Charcot-Marie-Tooth Disease

🧠 Standard of Care & Symptoms

Charcot-Marie-Tooth Disease (CMT) is a heterogeneous group of progressive, inherited peripheral neuropathies. Characterized by slowly progressive motor and sensory dysfunction, it primarily affects the distal extremities.

• Presentation: Key clinical signs.
  • *Distal Muscle Wasting:* Symmetrical wasting of intrinsic muscles of the feet and lower legs, leading to a classic "stork leg" or "inverted champagne bottle" appearance. Distal hand muscle wasting occurs in later stages.
  • *Foot Deformities:* High-arched feet (**pes cavus**) and clawed toes (**hammer toes**) are hallmarks, caused by imbalance in intrinsic foot muscle strength.
  • *Gait Abnormalities:* Weakness of ankle dorsiflexion causes a foot drop, resulting in a high-stepping, slapping gait.
  • *Sensory Loss:* Slowly progressive, symmetrical sensory loss to vibration, pain, and temperature in a stocking-glove pattern.
  • *Hyporeflexia:* Absent or markedly reduced deep tendon reflexes, particularly at the ankles.

🧬 Diagnostics & Genetic Pathophysiology

Diagnosis relies on electrophysiological nerve conduction studies, clinical presentation, and definitive multi-gene panels.

• Diagnostic Markers: Key criteria.
  • Nerve Conduction Studies (NCS): Distinguishes between demyelinating (CMT1) and axonal (CMT2) forms. CMT1 shows severely reduced motor conduction velocities (<38 m/s in the median nerve), while CMT2 shows reduced amplitudes with near-normal velocities.
  • Genetic Testing: Multi-gene panel sequencing isolates specific mutations. Duplication of the *PMP22* gene is the most common diagnostic finding.

Pathophysiology of Inherited Neuropathy

The degeneration of peripheral nerves is driven by distinct molecular defects, classifying CMT into demyelinating or axonal subtypes:

• CMT1 (Demyelinating Neuropathy): The most common form is **CMT1A**, accounting for 70% of cases. It is caused by a 1.4 Mb duplication on chromosome 17 containing the **PMP22** (Peripheral Myelin Protein 22) gene. Overexpression of PMP22 disrupts myelin assembly and maintenance. Repetitive demyelination and remyelination by Schwann cells produce a characteristic "onion bulb" histopathology.
• CMT2 (Axonal Neuropathy): Characterized by primary degeneration of the peripheral axon rather than the myelin sheath. **CMT2A** is the most common axonal form, driven by mutations in the *MFN2* (Mitofusin-2) gene. Mitofusin-2 regulates mitochondrial fusion and transport; its mutation halts axonal mitochondrial distribution, starving long motor and sensory axons.

💊 Symptom Management & Orthotics

No disease-modifying pharmacotherapy exists. Standard of care is supportive, focusing on physical therapy, orthotic devices, and surgical corrections.

Physical & Occupational Therapy

• Strengthening & Stretching: Low-impact aerobic conditioning and targeted stretching of the Achilles tendon help maintain joint range of motion and prevent contractures.
• Splints & Aids: Occupational therapy coordinates adaptive devices for fine motor tasks affected by hand intrinsic wasting.

Orthotics & Surgical Care

• Ankle-Foot Orthoses (AFOs): Lightweight, custom-molded AFOs are prescribed to stabilize the ankle, prevent foot drop, and reduce fall risk.
• Orthopedic Surgery: Indicated for severe, painful pes cavus or hammer toe deformities that do not respond to orthotic correction.
• Neurotoxic Medication Avoidance: Patients must strictly avoid neurotoxic drugs, particularly chemotherapeutics like **Vincristine**, which can trigger rapid, irreversible worsening of neuropathy.

🔬 Active Clinical Trials

Clinical trials are currently evaluating myelin-targeted therapies, gene replacement, and downstream pathway inhibitors.

🗺️ Next Steps After Diagnosis

If you have recently been diagnosed with Charcot-Marie-Tooth Disease, establish these clinical care pathways:

1. Confirm Genetic Subtype: Genetic testing is crucial to verify if the inheritance is autosomal dominant, recessive, or X-linked, guiding family planning and clinical trial screening.
2. Schedule a Physical Therapy Evaluation: Establish a regular low-impact exercise and stretching routine to preserve muscle length and joint mobility.
3. Obtain Custom AFOs: Work with an orthotist to evaluate the need for custom ankle-foot orthoses to stabilize your gait and prevent falls.
4. Review Medication Safety: Share your diagnosis with all prescribing physicians to ensure you strictly avoid neurotoxic drugs.

❓ Patient FAQ

Q: What is the difference between CMT1 and CMT2?
A: **CMT1** is a demyelinating disorder, meaning the protective myelin sheath surrounding the nerve is damaged, causing slow electrical signal conduction. **CMT2** is an axonal disorder, meaning the nerve fiber (axon) itself is damaged, reducing the strength of the electrical signal while the speed of conduction remains near normal.

Q: Will CMT affect my life expectancy?
A: For the vast majority of patients, CMT does not affect life expectancy. It is a slowly progressive condition that causes significant physical disabilities (particularly affecting mobility and hand function), but it rarely impacts breathing or other vital organs.